146 related articles for article (PubMed ID: 38378555)
21. Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study.
Sun CM; Toulmonde M; Spalato-Ceruso M; Peyraud F; Bessede A; Kind M; Cousin S; Buy X; Palussiere J; Bougouin A; Sautès-Fridman C; Fridman HW; Pulido M; Italiano A
Mol Cancer; 2024 Feb; 23(1):37. PubMed ID: 38374062
[TBL] [Abstract][Full Text] [Related]
22. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
23. An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade.
Zuo S; Wei M; Xu T; Kong L; He B; Wang S; Wang S; Wu J; Dong J; Wei J
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34949694
[TBL] [Abstract][Full Text] [Related]
24. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
25. Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
Hwang JK; Hong J; Yun CO
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33207653
[TBL] [Abstract][Full Text] [Related]
26. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
27. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
[TBL] [Abstract][Full Text] [Related]
28. The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Parato KA; Breitbach CJ; Le Boeuf F; Wang J; Storbeck C; Ilkow C; Diallo JS; Falls T; Burns J; Garcia V; Kanji F; Evgin L; Hu K; Paradis F; Knowles S; Hwang TH; Vanderhyden BC; Auer R; Kirn DH; Bell JC
Mol Ther; 2012 Apr; 20(4):749-58. PubMed ID: 22186794
[TBL] [Abstract][Full Text] [Related]
29. PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma.
Park JS; Lee ME; Kim J; Oh K; Lee N; Jung M; Jang WS; Ham WS
Cancer Cell Int; 2024 Jan; 24(1):50. PubMed ID: 38291394
[TBL] [Abstract][Full Text] [Related]
30. Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H; Ino Y; Todo T
Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F; Patil V; Yefet LS; Singh O; Liu J; Dang RMA; Yamaguchi TN; Daras M; Cloughesy TF; Colman H; Kumthekar PU; Chen CC; Aiken R; Groves MD; Ong SS; Ramakrishna R; Vogelbaum MA; Khagi S; Kaley T; Melear JM; Peereboom DM; Rodriguez A; Yankelevich M; Nair SG; Puduvalli VK; Aldape K; Gao A; López-Janeiro Á; de Andrea CE; Alonso MM; Boutros P; Robbins J; Mason WP; Sonabend AM; Stupp R; Fueyo J; Gomez-Manzano C; Lang FF; Zadeh G
Nat Med; 2023 Jun; 29(6):1370-1378. PubMed ID: 37188783
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
33. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus.
Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K
Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Italiano A; Bessede A; Pulido M; Bompas E; Piperno-Neumann S; Chevreau C; Penel N; Bertucci F; Toulmonde M; Bellera C; Guegan JP; Rey C; Sautès-Fridman C; Bougoüin A; Cantarel C; Kind M; Spalato M; Dadone-Montaudie B; Le Loarer F; Blay JY; Fridman WH
Nat Med; 2022 Jun; 28(6):1199-1206. PubMed ID: 35618839
[TBL] [Abstract][Full Text] [Related]
35. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK; Larkin J; Oya M; Thistlethwaite F; Martignoni M; Nathan P; Powles T; McDermott D; Robbins PB; Chism DD; Cho D; Atkins MB; Gordon MS; Gupta S; Uemura H; Tomita Y; Compagnoni A; Fowst C; di Pietro A; Rini BI
Lancet Oncol; 2018 Apr; 19(4):451-460. PubMed ID: 29530667
[TBL] [Abstract][Full Text] [Related]
36. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
Li M; Zhang M; Ye Q; Liu Y; Qian W
Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
[TBL] [Abstract][Full Text] [Related]
37. Role of Virus-Directed Therapy in Soft Tissue Sarcoma.
Chaudhary H; D'Angelo S
Curr Treat Options Oncol; 2022 Mar; 23(3):404-414. PubMed ID: 35258792
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
39. Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial.
Monga V; Miller BJ; Tanas M; Boukhar S; Allen B; Anderson C; Stephens L; Hartwig S; Varga S; Houtman J; Wang L; Zhang W; Jaber O; Thomason J; Kuehn D; Rajput M; Metz C; Zamba KD; Mott S; Abanonu C; Bhatia S; Milhem M
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34330766
[TBL] [Abstract][Full Text] [Related]
40. PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith HG; Mansfield D; Roulstone V; Kyula-Currie JN; McLaughlin M; Patel RR; Bergerhoff KF; Paget JT; Dillon MT; Khan A; Melcher A; Thway K; Harrington KJ; Hayes AJ
Clin Cancer Res; 2019 Jun; 25(11):3443-3454. PubMed ID: 30885937
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
